Methods for evaluating the benefits and harms of antenatal and newborn screening programmes adopted by health economic assessments: protocol for a systematic review.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
24 08 2021
Historique:
entrez: 25 8 2021
pubmed: 26 8 2021
medline: 28 8 2021
Statut: epublish

Résumé

Complex organisational arrangements are required to deliver antenatal and newborn screening programmes. Decision-makers consider the benefits and harms of screening when reviewing the evidence about these programmes. Economic evaluations contribute one important part of this assessment process. However, it is not fully understood what approaches health economic assessments have adopted to measure and value benefits and harms. This study aims to systematically review and critique the published and grey literature on methods for identifying, measuring and valuing the benefits and harms of antenatal and newborn screening adopted by health economic assessments. Nine bibliographic databases will be searched from 2000 onwards. These search strategies will be supplemented by manual reference searching of bibliographies, forward citation searching, contacts with experts, author searching and web searching for grey literature. Studies will be selected for review if they report health economic assessments of an antenatal or newborn screening programme. Assessments of title and abstracts and full reports will be undertaken independently with disagreements resolved through discussion. Data extraction will include fields to assess the reporting quality of the studies using the Consolidated Health Economic Evaluation Reporting Standards statement and a bespoke ancillary form to assess how benefits and harms have been accounted for. This is an evidence synthesis review from already published materials and hence ethics committee approval or written informed consent will not be required. Our results will be disseminated by publishing in high-impact peer-review journals and presenting at relevant conferences. CRD42020165236.

Identifiants

pubmed: 34429311
pii: bmjopen-2020-048031
doi: 10.1136/bmjopen-2020-048031
pmc: PMC8386210
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e048031

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: OR-A is a member of the Fetal, Maternal and Child Health reference group of the UK National Screening Committee (UK NSC). ST-P is a member of the UK NSC Adult Reference Group. SP, MEP, MY and NR declare that they have no competing interests.

Références

Int J Environ Res Public Health. 2014 May 19;11(5):5403-30
pubmed: 24852389
Med Decis Making. 2018 Apr;38(3):277-305
pubmed: 28990449
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Value Health. 2018 Sep;21(9):1033-1042
pubmed: 30224106
BMJ. 2018 May 09;361:k1612
pubmed: 29743278
Prenat Diagn. 2015 Jun;35(6):549-57
pubmed: 25644120
Health Technol Assess. 2013 Aug;17(35):1-90
pubmed: 23972041
Med Decis Making. 2016 Feb;36(2):176-86
pubmed: 26377370
Health Expect. 2015 Oct;18(5):1658-71
pubmed: 26039796
Pharmacoeconomics. 2011 Aug;29(8):641-52
pubmed: 21604821
Value Health. 2013 Mar-Apr;16(2):e1-5
pubmed: 23538200
Health Econ. 2001 Dec;10(8):775-8
pubmed: 11747056
Front Public Health. 2017 Mar 21;5:53
pubmed: 28377917
Health Econ. 2009 Apr;18(4):487-94
pubmed: 18615854
Value Health. 2017 Apr;20(4):651-661
pubmed: 28408008
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Public Health Genomics. 2011;14(4-5):298-306
pubmed: 20689248
Pharmacoeconomics. 2008;26(9):725-7
pubmed: 18767892

Auteurs

May Ee Png (ME)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Miaoqing Yang (M)

National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Nia Roberts (N)

Bodleian Health Care Libraries, University of Oxford, Oxford, UK.

Sian Taylor-Phillips (S)

Warwick Medical School, University of Warwick, Coventry, UK.

Oliver Rivero-Arias (O)

National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK oliver.rivero@npeu.ox.ac.uk.

Stavros Petrou (S)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH